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Abstract
Glucose transport to the fetus across the placenta takes place via glucose transporters in the opposing faces of the barrier
layer, the microvillous and basal membranes of the syncytiotrophoblast. While basal membrane content of the GLUT1
glucose transporter appears to be the rate-limiting step in transplacental transport, the factors regulating transporter
expression and activity are largely unknown. In view of the many studies showing an association between IGF-I and fetal
growth, we investigated the effects of IGF-I on placental glucose transport and GLUT1 transporter expression. Treatment of
BeWo choriocarcinoma cells with IGF-I increased cellular GLUT1 protein. There was increased basolateral (but not
microvillous) uptake of glucose and increased transepithelial transport of glucose across the BeWo monolayer. Primary
syncytial cells treated with IGF-I also demonstrated an increase in GLUT1 protein. Term placental explants treated with IGF-I
showed an increase in syncytial basal membrane GLUT1 but microvillous membrane GLUT1 was not affected. The placental
dual perfusion model was used to assess the effects of fetally perfused IGF-I on transplacental glucose transport and
syncytial GLUT1 content. In control perfusions there was a decrease in transplacental glucose transport over the course of
the perfusion, whereas in tissues perfused with IGF-I through the fetal circulation there was no change. Syncytial basal
membranes from IGF-I perfused tissues showed an increase in GLUT1 content. These results demonstrate that IGF-I, whether
acting via microvillous or basal membrane receptors, increases the basal membrane content of GLUT1 and up-regulates
basal membrane transport of glucose, leading to increased transepithelial glucose transport. These observations provide a
partial explanation for the mechanism by which IGF-I controls nutrient supply in the regulation of fetal growth.
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Introduction
Glucose, a primary substrate for fetal growth, is transported
across the human placenta via the GLUT1 glucose transporter
that is found in both the microvillous and basal membranes of the
syncytiotrophoblast barrier layer. GLUT1 glucose transporters are
asymmetrically distributed, being several fold higher on the
microvillous (maternal facing) than basal (fetal-facing) membrane
[1,2]. There is strong evidence that the basal membrane is the
rate-limiting step in transplacental glucose transport [3], thus
changes in basal membrane glucose transporter expression will
have significant consequences for the maternal-to-fetal transport of
glucose and for fetal growth. The importance of GLUT 1 in fetal
growth is clear. GLUT1 expression increases over the latter half of
gestation, concurrent with the increased rate of fetal growth in the
third trimester [1]. GLUT1 transporter expression is increased in
the basal membrane in diabetic pregnancies [4,5], while a
decrease in basal membrane GLUT1 expression has been shown
in altitude-induced hypoxia, concomitant with reduced fetal
growth [6]. In addition to the asymmetric distribution of the
GLUT1 glucose transporters, varied rates of glucose consumption
in syncytiotrophoblast cells have been shown to be an important
factor regulating directional flux of glucose from the maternal to
the fetal circulation [7].
Although these changes in GLUT1 expression are important for
fetal growth, the regulatory mechanisms controlling these changes
have yet to be elucidated. Our prior work has focused on factors
associated with the aberrant fetal growth observed in conditions
such as fetal growth restriction or macrosomia [4,8]. In this report
we have investigated the role of insulin-like growth factor-I (IGF-I)
in regulating syncytial GLUT1. There is evidence to support the
idea that both maternal and fetal IGF-I can regulate fetoplacental
growth. Multiple studies, including those examining the extremes
of birth weight in both normal and pathological conditions
indicate that maternal and fetal IGF-I levels are correlated with
birth weight [9–14]. Moreover natural experiments in the human
[15] or experimental manipulations in animals have shown that
changes in fetal growth are associated with alterations in IGF-I
[16–18].
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Despite the evidence demonstrating a role for IGF-I in
fetoplacental growth, there is an absence of information on the
specific mechanisms by which this interaction might be mediated.
One possible mechanism is the regulation by maternal and/or
fetal circulating IGF-I of the trans-syncytial nutrient fluxes
mediated via glucose, amino acid and other transporters. GLUT1
expression is regulated by IGF-I in a variety of tissues [19–22].
The type 1 IGF receptor is present on both the microvillous and
basal membrane of the syncytiotrophoblast [23,24]. It is possible
therefore that IGF-I, through the modulation of glucose
transporter expression on either the maternal or fetal side of the
syncytium, could have significant effects on fetal growth. We
hypothesized that GLUT1 protein expression on the basal
membrane of trophoblast cells is upregulated by IGF-I. In this
report we investigated the effects of IGF-I on the expression of
GLUT1 glucose transporter protein and glucose transport
function in trophoblast cells, placental explants and a placental
dual perfusion model.
Methods and Materials
Placental tissue/ethics statement
Human placental tissue was obtained from normal, term
singleton pregnancies following non-laboring, elective Cesarean
section. Written, informed consent was obtained using a protocol
approved by the New Jersey Medical School Institutional Review
Board (explant and cell studies) or a protocol approved by the
ethical committee of the Canton of Berne, Switzerland (perfusion
studies). Subjects were excluded if there was evidence of fetal
anomalies, intrauterine growth restriction, diabetes, hypertension,
anemia, tobacco or drug use or other medical or obstetric
complications.
Placental explants
Villous tissue was washed in cold PBS and dissected into 3–
5 mm fragments immediately following delivery. Dissected frag-
ments were maintained in ice-cold PBS during the dissection
period. Fragments (,3–5 mm, total of 2 g) were incubated in T75
tissue culture flasks in 40 mL of DMEM containing 5 mM
glucose, 0.5% BSA and 1% penicillin/streptomycin/gentamycin
for 3 hr. on an oscillating shaker in a humidified CO2 incubator.
Following this incubation period, IGF-I (200 ng/mL) was added
to the experimental samples. The incubation for control (no
addition) and experimental samples was then continued for
another 18 hr. After this incubation, the fragments were pelleted
by centrifugation at 5006g for 2 minutes and used for the
preparation of syncytial microvillous and basal membranes (see
below).
Placental perfusion
Perfusion was performed as described previously [25,26].
Immediately following elective cesarean section cannulae were
placed in the artery and the vein of a placental lobule (cotyledon)
to establish the fetal circulation; four needles located within the
intervillous space served to provide the maternal circulation. The
maternal and fetal circulations were perfused with a medium
composed of NCTC 135 and Earle’s buffered salt solution (2:1)
containing 10 g/L dextran 40, 40 g/L human serum albumin and
2500 IU/L heparin. The maternal perfusate was equilibrated with
an atmospheric gas mixture and contained 6 mM D-glucose. The
fetal circulation was gassed with 95% N2/5% CO2 and contained
3 mM D-glucose. The intervillous space (maternal circulation) was
perfused with medium containing [3H] 3-O-methyl-D-glucose and
[14C] L-glucose (0.064 and 0.032 mCi/mL, respectively) for
periods of 30 minutes (open fetal circulation) to establish rates of
transfer from the maternal to fetal circulation. For all placentas
used in the perfusion studies, tissue samples were taken from
placental lobules that were not used for perfusion. These are
identified as ‘‘immediate control’’ samples. Villous tissue from
immediate controls was prepared by removal of a decidual layer
and the chorionic plate. This tissue was then washed in ice cold
0.9% saline and utilized for the preparation of syncytial
microvillous and basal membranes. Following termination of the
perfusion, the perfused lobule was excised and villous tissue was
prepared in the same manner to yield control or experimental
(IGF-I treated) samples.
Syncytial membrane preparation
Washed villous tissue or previously incubated villous tissue
fragments were used to prepare syncytial microvillous and basal
membranes using a previously described method [4].
BeWo cells
BeWo cells (b30 subclone, obtained from Dr. K. Audus,
University of Kansas [27]) were cultured in DMEM/F12
containing 10% FBS. Cells used for the measurement of GLUT1
protein expression were plated in 6-well culture plates and
incubated in DMEM/F12/FBS until the cultures were 70–80%
confluent. Cells were then switched to serum-free DMEM
containing 5 mM glucose and 0.5% BSA for 24 hr. prior to
incubation in the same medium without or with IGF-I (200 ng/
mL). After incubation cells were washed62 with cold PBS,
extracted with RIPA buffer and extracts were frozen at 280uC
until analysis. In the time course experiments where the incubation
period extended to 48 hr., medium and IGF-I were replaced after
24 hr. Transepithelial glucose transfer and glucose uptake
experiments in BeWo choriocarcinoma monolayers were per-
formed as described previously [3], including measurements of
transepithelial electrical resistance to ensure presence of a
monolayer. Prior to measurement, growth medium was replaced
by DMEM/0.5% BSA containing 5 mM glucose for 24 hr.
followed by a further 24 hr. incubation performed in the presence
or absence of IGF-I (200 ng/mL) added to both apical and basal
reservoirs. Passive transport was determined by performing
experiments in the presence of the glucose transport inhibitor,
phloretin (2 mM) in both apical and basal reservoirs. The
difference between total and passive glucose transport/uptake
was taken as the rate of carrier-mediated glucose transport.
Primary syncytial cells
Cytotrophoblast cells were prepared as described previously
[28,29]. Cells were plated at a density of 0.46106 cells/cm2 in 6-
well plates and incubated in keratinocyte growth medium (KGM;
Lonza, Walkersville, MD) containing 10% FBS under a humid-
ified air/5% CO2 atmosphere. Purity and syncytialization were
tested as described previously [30] (data not shown). Medium was
changed every 24 hr. and at 66 hr. medium was switched to
serum-free DMEM containing 5 mM glucose and 0.5% BSA for
18 hr. prior to incubation in the same medium without or with
200 ng/mL IGF-I for a further 24 hr.
Immunoblotting
To determine GLUT1 protein expression, slot-blotting was
performed on membrane samples as described previously [4] using
a polyclonal anti-GLUT1 antibody (1:1,000). The membrane was
washed with TBS containing 0.05% Tween-20 (TBST; 2615 min,
265 min) then incubated for a further 30 min with an HRP-
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coupled anti-rabbit IgG secondary antibody (1:40,000) at room
temperature. Detection and visualization were performed using
chemiluminescence on a Bio-Rad ChemiDoc MP imager. GLUT1
displayed a single band on Western blots as demonstrated
previously [4]. Band densities were measured using Image J (NIH).
Other assays
Protein concentration was measured by the Bradford assay [31]
and glucose concentrations were measured using a hexokinase-
glucose-6-phosphate dehydrogenase coupled enzyme assay [32].
Data analysis
All data is presented as mean 6 SEM. BeWo GLUT1
expression and glucose transport, syncytial and explant GLUT1
expression data were analyzed by paired t test (two-tailed) or
ANOVA (Dunnett’s test). Perfusion GLUT1 expression was
assessed by a one-sample t test. Glucose transport in the perfusion
model was analyzed by repeated measures ANOVA with a linear
trend post hoc test.
Materials
Insulin-like growth factor I (IGF-I) was obtained from Life
Technologies (Grand Island, NY) and the anti-GLUT1 antibody
was obtained from Thermo Scientific (Waltham, MA). Protease
inhibitor and the HRP-labeled anti-rabbit IgG antibodies were
obtained from Sigma Chemical Company (St Louis, MO). [3H] 2-
deoxy-D-glucose was obtained from American Radiochemicals (St
Louis, MO). [3H] 3-O-methyl-D-glucose and [14C] L-glucose were
obtained from New England Nuclear (Boston, MA). Nitrocellulose
membranes (Hybond ECL) were obtained from GE Healthcare
and chemiluminescence kits (Super Signal Western Pico) were
obtained from Pierce Biotechnology (Rockford, IL. Permeable
supports (Transwell) for growing BeWo cells were obtained from
Corning (Pittsburgh, PA). All other reagents were obtained from
Sigma Chemical Co. (St. Louis, MO) or Bio-Rad (Hercules, CA).
Results
IGF-I and GLUT1 expression in BeWo cells
Initial experiments were conducted to examine the IGF-I/
GLUT1 dose response and time course. For dose response
experiments BeWo cells were treated with IGF-I (0–200 ng/mL)
for 24 hr. following serum-free incubation. GLUT1 protein
expression was measured by slot blotting after extraction of the
cell protein. GLUT1 protein expression, normalized to ß-actin
and adjusted to a value of unity in the absence of IGF-I, is shown
in Figure 1A. GLUT1 shows an increasing and saturable response
to increasing doses of IGF-I, reaching a maximum well below the
dose of 200 ng/mL used in the rest of the experimental
procedures. The IGF-I concentration (200 ng/mL) used in the
remainder of these studies (with the exception of the perfusion
studies) was chosen as a level that produces maximal stimulation
and is an approximation of the normal maternal concentration of
circulating IGF-I. We chose to perfuse the fetal circulation with an
IGF-I concentration of 100 ng/mL, closer to that of the
circulating fetal level. The actual IGF-I concentrations to which
the syncytial microvillous and basal type 1 IGF receptors are
exposed in vivo is difficult to assess, given the presence of multiple
IGF-I binding proteins (both soluble and membrane-bound) as
well as competing ligands such as IGF-II.
The time course of GLUT1 response to treatment with IGF-1
(200 ng/mL) is shown in Figure 1B. This data shows that
significantly increased levels of GLUT1 were observed by 12 hr.
following the initiation of treatment (p,0.01, ANOVA; n=3).
GLUT1 was maximally increased by 24 hr. with no further
changes as a result of a further 24 hr. of incubation. In view of
these results we chose to perform the remainder of the experiments
over a 24 hr. time period to enable similar conditions for BeWo,
primary syncytial and explant experiments while ensuring that
effects observed were maximal.
IGF-I effects on BeWo transport
BeWo cells plated on permeable Transwell inserts were treated
with IGF-I (200 ng/mL, 24 hr.) following serum-free incubation.
Transepithelial transport of glucose across the BeWo monolayer
was measured as the phloretin-inhibitable rate of appearance of
glucose in the lower (’’fetal side’’) reservoir following transfer from
the upper (‘‘maternal side’’) reservoir. Figure 2A shows that the
rate transfer of glucose across the monolayer was increased 2-fold
by IGF-I, from 0.8560.28 nmol/min to 1.7160.26 nmol/min
(p,0.05, paired t test; n = 6).
Using BeWo cells plated on permeable Transwell inserts,
glucose uptake into BeWo cells was measured from the upper
reservoir, across the apical membrane or from the lower reservoir,
across the basolateral membrane using a radiolabeled tracer ([3H]
Figure 1. IGF-I effects on BeWo cells. (A) Dose-response: Serum-
starved BeWo cells were treated for 24 hr. with IGF-I at doses ranging
from 5 to 200 ng/mL. Extracted cell samples were used to measure
GLUT1 by slot blotting. The graph shows that treated BeWo cells
demonstrate a GLUT1 dose response to IGF-I terminating at a level 1.6-
fold greater than control; (p,0.05, ANOVA, n = 3). (B) Time course:
Serum-starved BeWo cells were treated with IGF-1 (200 ng/mL) for
times ranging from 6 hr. to 48 hr. Extracted cell samples were used to
measure GLUT1 by slot blotting. The graph shows that increased levels
of GLUT1 were observed by 12 hr. with maximal levels achieved by
24 hr. (p,0.01, ANOVA, n= 3).
doi:10.1371/journal.pone.0106037.g001
Regulation of Trophoblast GLUT1 by IGF-I
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e106037
2-deoxy-D-glucose). Uptake was measured in serum-starved
control and IGF-I treated cells. Figure 2B shows the results of
these experiments, demonstrating that while uptake across the
apical membrane was unchanged by IGF-I treatment, uptake
across the basolateral membrane of the BeWo cells was increased
by almost 60% in cells treated with IGF-I (p,0.01, paired t test;
n = 4).
IGF-I and GLUT1 expression in primary syncytial cells
We compared GLUT1 expression in primary syncytial cells
following incubation in the presence and absence of IGF-I.
Primary cytotrophoblast cells were incubated in KGM/FBS for
66 hr. after plating to maximize syncytialization. The cells were
then serum-starved by overnight incubation in DMEM/0.5%
BSA and incubated for a further 24 hr. in DMEM/0.5% BSA in
the presence or absence of IGF-I (200 ng/mL). Following
treatment, cells were washed63 with cold PBS and extracted
with RIPA. GLUT1 expression in syncytial samples was measured
by slot blotting and normalized to ß-actin expression. The results
(Figure 3A) show that IGF-I treatment increased syncytial
expression of GLUT1 (p,0.05, paired t test, n = 4).
IGF-I and GLUT1 expression in placental explants
We compared GLUT1 expression in syncytial microvillous and
basal membranes prepared from explants which had been
incubated in the presence or absence of IGF-I (200 ng/ml) for
18 hr. Figure 3B shows the results of Western blotting analyses for
GLUT1 in explant microvillous and basal membrane fractions.
GLUT1 protein expression in microvillous membranes from IGF-
I-treated explant preparations was not different from that in
control explants. Analysis of basal membrane fraction GLUT1
however revealed that IGF-I treated explants displayed GLUT1
levels that were significantly greater than the comparable,
untreated membrane fraction (p,0.01, paired t test, n = 6).
Placental perfusion - glucose transfer
We performed separate control and experimental perfusions.
Both employed an open maternal perfusion circuit and the
protocol shown in Figure 4 was used for the fetal perfusion circuit.
The only difference between the perfusion protocols was that in
the experimental group, after 120 min of initial perfusion, the fetal
Figure 2. GLUT1 transport and IGF-I in BeWo cells. (A)
Transepithelial transport: BeWo cell monolayers plated on permeable
inserts were treated for 24 hr. with 200 ng/ml IGF-1 following serum-
starvation. Measurements of the transepithelial transport of glucose
were performed in the presence and absence of 2 mM phloretin (see
Methods). Transcellular transport was calculated as the phloretin-
inhibitable fraction of transepithelial transport. The results showed that
treated cells had an increased rate of transcellular glucose transport
(p,0.05, paired t test, n = 4). (B) Cellular uptake: BeWo cell monolayers
plated on permeable inserts were serum starved then treated for 24 hr.
with 200 ng/mL IGF-1. Following treatment, uptake of [3H] 2-deoxy–D-
glucose into the cells across the apical or basolateral face was
measured. The rate of glucose uptake across the apical face was not
altered by IGF-I treatment. The rate of uptake across the basolateral face
was increased by IGF-I treatment (p,0.01, paired t test, n = 4).
doi:10.1371/journal.pone.0106037.g002
Figure 3. IGF-I and GLUT1 expression in primary syncytial cells
and placental explants. (A) Syncytial cells: Serum-starved syncytial
cells were treated for 24 hr. with 200 ng/mL IGF-1. GLUT1 measurement
in cell extracts by slot blotting showed a significant increase as a result
of IGF-I treatment (p,0.05, paired t test, n = 4). (B) Explants: Placental
explants were serum-starved for 3 hr. then incubated with 200 ng/mL
for 18 hr. Following incubation the explants were processed to produce
microvillous and basal membrane fractions. GLUT1 was measured in
these fractions by slot blotting. There was no change in microvillous
membrane GLUT1 content as a result of IGF-I treatment however there
was a substantial increase in GLUT1 in the basal membrane fraction (p,
0.01, paired t test, n = 6).
doi:10.1371/journal.pone.0106037.g003
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circuit was perfused with IGF-I (100 ng/ml) whereas the control
group contained no addition. In both groups, glucose transfer from
the maternal to fetal circulation was measured using a radiolabeled
tracer ([3H] 3-O-methyl-D-glucose, 3-OMG). The percent trans-
fer from maternal to fetal circulation was calculated from the
radiolabeled tracer levels and fetal flow rate. The results in
Figure 5A show that for the control perfusions the transfer of 3-
OMG decreased in a linear manner over the perfusion period (p,
0.01, repeated measures ANOVA, linear trend post test; n = 4). By
contrast in the experimental (IGF-I-treated) group, the transfer of
3-OMG was maintained throughout the perfusion period.
Diffusional transfer, measured as transfer of [14C] L-glucose,
remained constant over the perfusion period in both groups.
Placental perfusion - GLUT1 expression
Syncytial microvillous and basal membranes were prepared
from both the control and experimental (IGF-I treated) perfused
tissue. In order to control for differences in function over time
following removal from the uterus, membranes were also
generated from the un-perfused villous tissue of both groups,
obtained at the time of the initiation of the perfusion (‘‘immediate
controls’’). GLUT1 protein expression was measured by slot-
blotting both the immediate control and perfused samples. The
results of these measurements are given in Figure 5B, where
GLUT1 protein expression in the microvillous and basal
membranes of the control and experimental groups are given as
a fraction of GLUT1 expression in the corresponding immediate
control samples. Microvillous GLUT1 expression was reduced by
27% in the control perfusion and by 35% in the IGF-I perfusion
compared to their respective immediate controls (p,0.05, one
sample t test, n = 4). Basal membrane GLUT1 was reduced by
43% in the control perfusion compared to the immediate controls,
but in the IGF-I perfusions basal membrane GLUT1 expression
was increased by 38% compared to the immediate controls (p,
0.05, one sample t test, n = 4).
Discussion
These studies examined the role of IGF-I in the regulation of
GLUT1 protein expression in trophoblast cells. We hypothesized
that IGF-I would up-regulate GLUT1 expression on the basal
surface, the rate limiting step in maternal to fetal glucose transport.
Several different trophoblast models were used to examine the
effects of IGF-I. We found that IGF-I increased GLUT1
expression in BeWo choriocarcinoma cells, associated with an
increase in glucose uptake across the basolateral but not the apical
surface. IGF-I treatment also increased BeWo transepithelial
glucose transport. Treatment of primary syncytial cells with IGF-I
increased GLUT1 expression. Administration of IGF-I to human
placental explants increased syncytial basal membrane GLUT1
content compared to untreated explants, whereas microvillous
membrane content was not altered. In placental perfusion studies,
control perfusions demonstrated a significant decrease in the
maternal-to-fetal transfer of glucose over the course of the
perfusion compared to experiments in which the fetal perfusate
contained IGF-I. In the control perfusions there was a decrease in
basal membrane GLUT1 protein expression over the course of the
experiment. In comparison, placental tissue perfused with IGF-I
via the fetal circulation demonstrated an increase in basal
membrane GLUT1. These results support the hypothesis that
GLUT1 protein expression on the basal membrane of human
trophoblast cells is regulated by IGF-I. This has significant
consequences for conditions in which there are changes in
circulating IGF-I concentrations such fetal growth restriction,
preeclampsia or macrosomia.
Investigations of processes in the human placenta face a number
of challenges as a result of the nature of tissue/cellular structures,
Figure 4. Timeline of control and experimental perfusions. A stabilization phase of 30 minutes (open fetal circulation) and 60 minutes (closed
fetal circulation) was used in both control and experimental perfusions. Maternal perfusion was started 30 min after the beginning of the fetal
circulation. Between 90 and 120 min the intervillous space was perfused with medium containing [3H] 3-O-methyl-D-glucose and [14C] L-glucose
(0.064 and 0.032 mCi/ml, respectively) to establish rates of transfer from the maternal to fetal circulation (open fetal circulation). After the initial
sampling from the maternal and fetal circulations, the fetal circulation was closed and perfusion was continued for 2 hours. During this period, the
fetal perfusate in the experimental perfusions contained IGF-I (100 ng/mL) whereas the control perfusions contained no addition. After another 30-
minute phase of perfusion with radiolabeled glucose on the maternal side and open circulation on the fetal side, samples were obtained from both
circulations. The fetal circulation was again closed and perfusion was continued for another 2 hours containing IGF-I (experimental) or no addition
(control). After a final 30 minute period of perfusion with radiolabeled glucose, perfusions were terminated following the final sampling from fetal
and maternal circulations.
doi:10.1371/journal.pone.0106037.g004
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requiring utilization of a variety of experimental models. We have
used choriocarcinoma cells, primary trophoblast, placental
explants and in vitro perfusion to examine the role of IGF-I in
the regulation of GLUT1. BeWo choriocarcinoma cells model the
syncytial layer in vivo, enabling measurement of transport
properties that cannot be performed with primary syncytial cells
due to the absence of a transporting monolayer. Limitations of the
BeWo model are that while they are trophoblastic in nature, they
are transformed cells that may respond differently compared to
syncytial cells in vivo. Primary cytotrophoblast cells aggregate,
fuse and differentiate to form syncytial cells, however current
techniques do not allow for generation of a confluent monolayer,
precluding the measurement of transepithelial glucose transfer or
transport of glucose across the microvillous and basal membranes.
Placental explants cannot be used for the measurement of
transport but are comprised of the original cellular components
of the tissue in their in vivo configuration and are therefore
appropriate for examining the response of syncytial cells to
external agents such as IGF-I. However previous studies have
noted that syncytial degeneration begins to occur after six hours in
culture [33,34]. In these experiments we used matched control
and experimental samples from the same placenta, so that any
effects of syncytial degeneration on the experimental samples were
also observed in the control samples. The placental perfusion
model is the closest to the in vivo situation. It allows for
measurements of both transporter expression and maternal-fetal
transport of glucose, albeit under conditions which are, in part,
non-physiological (e.g perfusate with a high PO2 but low O2
content). Used singly, each of the models cited above has flaws that
preclude definitive conclusions. Used in combination, the com-
monality of results between the models gives us confidence in the
results reported here.
As we noted in an earlier publication, there is very little GLUT1
present in syncytiotrophoblast which is not localized to the
microvillous or basal membrane [1], and so it seems unlikely that
the changes in basal GLUT1 are a result of relocalization of
intracellular GLUT1. If the increase in basal membrane GLUT1
had resulted from relocalization of microvillous GLUT1 to the
basal membrane, one might expect a decrease in microvillous
GLUT1 concurrently with the increase in basal membrane
GLUT1. The absence of a significant decrease in microvillous
GLUT1 suggests that microvillous to basal redistribution is not
occurring. Combined with the overall increase in GLUT1 noted in
the primary trophoblast experiments, these elements point to an
overall increase in GLUT1 protein expression. The increase in
syncytial GLUT1 as a result of IGF-I treatment is supported by
the observations of Jones et al who observed an increase in BeWo
GLUT1 after transfection of cells with an adenoviral vector-
human IGF-I construct [35].
Not addressed in these studies is the mode of action of IGF-I. It
is quite possible that IGF-I has more than one mode of action in
stimulating GLUT1 expression and activity. For example the
causes of the degenerative changes in the syncytium are unknown
but given the anti-apoptotic nature of IGF-I, it is possible that the
differences in GLUT1 expression in the IGF-I-treated explants or
in the perfusion may be related to IGF-I inhibition of (syncytial)
apoptosis or other IGF-I effects promoting or supporting syncytial
viability. IGF-I action to sustain tissue viability is supported by the
nature of IGF-I effects on glucose transport in the perfusion
experiments, where the progressive loss of glucose transfer capacity
is prevented by IGF-I. While the time course of IGF-I action in the
perfusion is shorter than that employed in the cell or explant
experiments, we have previously shown the effects of hypoxia
mimetics on GLUT1 expression over a similar time scale [36].
While not the primary purpose of these studies, it is interesting to
note that addition of IGF-1 to media in experiments involving
placental perfusion/explants might well improve our ability to
mimic the in vivo maternal environment, maintain tissue viability
and extend the period of experimentation.
Other verified trophoblast glucose transporters are GLUT3,
GLUT8 and GLUT9 [35,37,38]. GLUT3 is present only on the
microvillous/apical membrane [37], and given the substantial
quantity of GLUT1 on this face of the syncytial cell compared to
the basal membrane, it is unlikely that any effects of IGF-I on
GLUT3 will alter transplacental glucose transport. GLUT8 has
Figure 5. Placental perfusion. Placental perfusion was performed as
described in the text, according to the protocol in Figure 4. (A)
Maternal-fetal glucose transport. At t = 2, 4.5 and 7 hr., samples were
taken from the maternal and fetal circulations and the % maternal-fetal
transfer of [3H] 3-O-methyl-D-glucose and [14C] L-glucose was
calculated for the control perfusions and those that were perfused
with IGF-I (100 ng/mL). There was a significant linear decrease in the
transfer of [3H] 3-O-methyl-D-glucose in the control perfusions over
time (p,0.01, repeated measures ANOVA, linear trend post test; n = 4)
whereas there was no change in % transfer in the IGF-I perfusions. In
addition, no changes were noted in the diffusional transfer component
in either the control or experimental group, shown here as the
combined data. (B) GLUT1 protein expression. Immediately prior to
perfusion, tissue samples were taken from non-perfused areas for
preparation of microvillous and basal membrane fractions (immediate
controls). After perfusion, the perfused lobules were dissected out and
used for preparation of microvillous and basal membrane fractions. The
two membrane fractions were slot-blotted to determine GLUT1 protein
expression. The results show the effects of IGF-I on microvillous and
basal membrane GLUT1 in the perfusions as a fraction of the GLUT1
protein expression in the respective immediate control samples. In the
microvillous and basal samples from control perfusions there was a
decrease in GLUT1 relative to the expression prior to perfusion. A similar
result was obtained for the basal membrane from the control perfusion,
however the basal membrane GLUT1 expression from the IGF-I
perfusion was increased (p,0.05, one sample t test, n = 4).
doi:10.1371/journal.pone.0106037.g005
Regulation of Trophoblast GLUT1 by IGF-I
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e106037
been described in human syncytial cells [35] but since it is
localized to the late endsome/lysosomal compartments [39] it is
unlikely to be involved in transepithelial transfer. While GLUT9a
and 9b protein were both increased by IGF-I in BeWo cells, only
GLUT9b, the syncytial microvillous form [38] relocalized to the
plasma membrane [35], suggesting that IGF-I effects on this
protein will not have significant effects on transplacental glucose
transport.
Another aspect worthy of consideration is the location of IGF-I
action. It is likely that IGF-I is able to act on type 1 IGF receptors
on both the microvillous and basal/basolateral membranes in the
cell models used here. It is less likely however that external,
hydrophilic agents such as IGF-I are able to reach the basal (fetal-
oriented) face of the syncytial cells in the cultured explants and so
we must assume that the IGF-I added to explants only interacts
with the microvillous (maternal-facing) surface of the syncytial
cells. In the perfusion, by contrast, IGF-I was added only to the
fetal circulation, thus its action was limited to receptors on the
basal face of the syncytium. Despite this, our results show that
IGF-I has the same effect whether it binds to receptors on the
maternal- or fetal-facing membrane, increasing GLUT1 on the
syncytial basal membrane. As the type 1 IGF receptor is found on
both microvillous and basal membranes [13,40], the effects of
IGF-I on syncytial basal membrane GLUT1 expression can thus
be mediated by changes in type 1 IGF receptor ligands in either
the maternal or fetal circulation Similarly, changes in presentation
of the type 1 receptor on either the microvillous or basal
membrane may also influence basal membrane GLUT1 levels.
The role played by IGF-I as a growth factor is widely
recognized. Equally, its clear association with fetoplacental growth
has long been known. The results presented here connect these
processes and provide a mechanism by which IGF-I is able to
regulate fetal growth, through its up-regulation of the GLUT1
glucose transporter protein on the basal membrane of the
syncytiotrophoblast. Agents such as IGF-I which alter basal
GLUT1 expression will have significant effects on placental
glucose transfer capacity and consequently on the levels of fetal
circulating glucose. There is also strong evidence for IGF-I
involvement in the regulation of placental amino acid transporters
[41–45] and possibly fatty acid transport [46]. Experiments
employing maternal nutrient restriction in the baboon showed a
reduction in GLUT1 expression in syncytial microvillous GLUT1
expression, as well as reduction in amino acid transporter protein
expression concomitant with inhibition of IGF-I/insulin signaling
[47]. It seems plausible therefore to postulate that IGF-I plays a
key role in regulating the placental transport of essential nutrients
from mother to fetus. It will be crucial therefore in controlling the
rate of fetal growth through regulation of the fetal nutrient supply.
We have observed that reduced placental glucose transfer into the
fetal circulation is associated with low fetal circulating glucose, a
reduced fetal insulin level and reduced birth weight [48]. It is
probable therefore that an alteration in fetal and/or maternal
IGF-I, acting via changes in transporter expression, is one of the
key pathways by which fetal growth is coupled to nutrient supply.
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